老年尿路上皮细胞癌患者免疫检查点抑制剂治疗进展  

Advancements in the management of immune checkpoint inhibitors for urothelial carcinoma among geriatric patients

作　　者：刘文博[1] 李琳[2] Liu Wenbo;Li Lin(Department of Oncology,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;Graduate School Peking Union Medical College,Beijing 100730,China)

机构地区：[1]北京医院肿瘤内科、国家老年医学中心、中国医学科学院老年医学研究所,北京100730 [2]中国医学科学院,北京协和医学院研究生院,北京100730

出　　处：《中华老年医学杂志》2024年第4期538-543,共6页Chinese Journal of Geriatrics

摘　　要：尿路上皮细胞癌(UCC)是一种起源于尿路器官上皮的恶性肿瘤,手术是目前治疗UCC的主要方法之一,但目前的治疗效果依旧不佳。免疫治疗作为近年来兴起的一种新型治疗手段,旨在阻断肿瘤蛋白或与肿瘤蛋白结合的免疫细胞受体,从而激活免疫细胞,杀伤癌细胞而发挥作用。老年UCC患者的治疗方案的选择往往因其病理、生理特点而具有一定的复杂性,但由于老年人群体的特殊性,目前尚缺乏有关免疫检查点抑制剂治疗老年患者的大型随机对照试验。本文参考纳人老年UCC患者的临床试验,对免疫抑制剂在老年患者中的应用进行综述。Urothelial cell carcinoma(UCC)is a malignant tumor originating from the epithelium of the urinary tract organs.Surgery is one of the main treatment methods for UCC,but the current treatment effect remains poor.Immunotherapy,as a new type of treatment emerging in recent years,aims to block tumor proteins or immune cell receptors that bind to tumor proteins,thus activating the immune cells to work by killing cancer cells.The choice of therapeutic regimen for elderly UCC patients is often complicated by their pathological and physiological characteristics,but due to the special characteristics of the elderly population,there is a lack of large-scale randomized controlled trials on immune checkpoint inhibitors for the treatment of elderly patients.This article reviews the use of immunosuppressants in elderly patients with reference to clinical trials that included elderly UCC patients.

关 键 词：免疫检查点抑制剂 尿路上皮癌 

分 类 号：R737.1[医药卫生—肿瘤]